Skip to Main Content

A new era in type 1 diabetes treatment

With guest Matthias G. von Herrath
Dean Ford and Matthias von Herrath
Matthias G. von Herrath and Dean Henri Ford

June 21, 2023 

GuestMatthias G. von Herrath
Listen Time: 24m 47s

Could insulin dependency be a burden of the past for patients with type 1 diabetes? Matthias von Herrath, M.D., scientific director of the Diabetes Research Institute, is hopeful.  Dr. von Herrath joined Inside U Miami Medicine to share how he and his teams are working on the ultimate T1D moonshot: To restore or preserve natural insulin production and normalize blood sugar levels without imposing other risks that accompany immune suppression.

In episode one of this two-part conversation, Dr. von Herrath reviews the current understandings of the pathogenesis of T1D and describes the mechanisms of the first FDA-approved treatment for delaying T1D for those at risk: Tzield (teplizumab-mzwv), an anti-CD3 monoclonal antibody.

Listen on Apple Listen on iHeart Listen on Spotify


Matthias G. von Herrath

Matthias G. von Herrath

Director Diabetes Research Institute, Endocrinology, Diabetes and Metabolism

Biography: A native of Germany, Dr. von Herrath earned his medical degree in 1988 from Freiburg Medical School, where he also completed a Ph.D. equivalent thesis on biochemistry. His postdoctoral training included an intensive care residency at Diakonie Hospital, Freiburg; a fellowship in medicine/immunology at Freiburg Medical Center; and a fellowship in virology at Scripps Research...
View Full Profile >